- Goldman downgrades Teva Pharmaceutical (TEVA -1.8%) to Sell, price target is $40.
- The company's focus on pipeline rebuilding has left it "relatively quiet" in an environment "awash with accretive deal activity," analyst Jami Rubin notes.
- Of course there's also the whole generic Copaxone problem which Rubin says will leave the company "facing fewer options with respect to capital allocation."
- Previously: Patent invalidation dents TEVA's plan to transition Copaxone patients to longer-acting formulation.
at Zacks.com (Nov 5, 2014)